# US 2026/0097191 A1 · System for accessing a cochlear implant lead insertion site

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097191 A1
- Document ID: US20260097191A1
- Status: Published application
- Kind: A1
- Application number: 19/418,146
- Filed: 2025-12-12
- Published: 2026-04-09
- Earliest claimed: 2024-09-26
- Assignees: Spiral Therapeutics Inc.
- Applicants: Spiral Therapeutics, Inc.
- Inventors: Hugo Peris; Benson Jung; Kevin W. Sacherman
- Web page: https://patentgrep.com/patent/US20260097191A1

## CPC

- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61M 39/10: Tube connectors or tube couplings
- A61B 1/00018: {using electrical cables}
- A61B 1/00045: {Display arrangement}
- A61B 1/00071: {Insertion part of the endoscope body (A61B1/0055 takes precedence)}
- A61B 1/00114: {Electrical cables in or with an endoscope}
- A61B 1/00119: {Tubes or pipes in or with an endoscope}
- A61B 1/015: Control of fluid supply or evacuation
- A61B 1/05: characterised by the image sensor, e.g. camera, being in the distal end portion
- A61B 1/0676: {at distal tip of an endoscope}
- A61B 1/0684: {using light emitting diodes [LED]}
- A61B 1/227: for ears, i.e. otoscopes
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61M 31/00: Devices for introducing or retaining media, e.g. remedies, in cavities of the body (A61M25/00 takes precedence {; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008})
- A61N 1/0541: {Cochlear electrodes}
- A61M 2039/0009: {Assemblies therefor designed for particular applications, e.g. contrast or saline injection, suction or irrigation}
- A61M 2039/1027: {Quick-acting type connectors}
- A61M 2202/0007: introduced into the body
- A61M 2202/04: Liquids
- A61M 2205/502: User interfaces, e.g. screens or keyboards
- A61M 2210/0662: Ears
- A61M 2210/0668: Middle ear
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Systems and methods can be employed for access to the middle ear for delivery of a formulation to a targeted site under direct visualization. The formulation, in some cases, can be delivered to a cochlear implant lead insertion site where a lead of a cochlear implant device enters a patient's cochlea.

## Claims

### Claim 1

A system for delivering a self-gelling therapeutic formulation at a cochlear implant lead insertion site of a cochlea, comprising:
a transmastoid injector tool having a therapeutic gel delivery shaft positionable adjacent to a cochlear implant lead in a transmastoid surgical opening such that a distal port of therapeutic gel delivery shaft is configured to deposit a self-gelling therapeutic formulation at a cochlear implant lead insertion site of a cochlea, the transmastoid injector tool comprising:
a handle connected to the therapeutic gel delivery shaft and a visualization shaft that both extend distally from the handle; and
a fluid input port on the handle to connect with a treatment actuator device configured to deliver the self-gelling therapeutic formulation through a gel delivery lumen of the therapeutic gel delivery shaft and out of the distal port of the therapeutic gel delivery shaft toward the cochlear implant lead insertion site of the cochlea,
wherein the distal port of the therapeutic gel delivery shaft is positioned distally of the visualization shaft so that the visualization shaft is configured to provide simultaneous imaging of both the therapeutic gel delivery shaft and the self-gelling therapeutic formulation deposited at the cochlear implant lead insertion site of the cochlea.

### Claim 2 (depends on 1)

The system of claim 1, wherein the therapeutic gel delivery shaft is sized to extend through the transmastoid surgical opening behind an ear so that the distal port of the therapeutic gel delivery shaft is adjacent the cochlear implant lead insertion site at the cochlea when the distal port of the therapeutic gel delivery shaft deposits the self-gelling therapeutic formulation to seal the cochlear implant lead insertion site.

### Claim 3 (depends on 2)

The system of claim 2, wherein the distal port of the therapeutic gel delivery shaft is further configured to deposit the self-gelling therapeutic formulation at the cochlear implant lead insertion site of the cochlea subsequent to the cochlear implant lead being implanted within the cochlea.

### Claim 4 (depends on 2)

The system of claim 2, wherein the distal port of the therapeutic gel delivery shaft is configured to deposit the self-gelling therapeutic formulation at the cochlear implant lead insertion site prior to the cochlear implant lead being implanted within the cochlea.

### Claim 5 (depends on 1)

The system of claim 1, further comprising a reservoir containing the self-gelling therapeutic formulation for communication through the fluid input port on the handle of the transmastoid injector tool, the reservoir containing the self-gelling therapeutic formulation comprising: a first functional polymer, a crosslinker, and an anti-inflammatory therapeutic agent configured to provide a sustained release into the cochlea via the cochlear implant lead insertion site of the cochlea.

### Claim 6 (depends on 5)

The system of claim 5, wherein the self-gelling therapeutic formulation comprises the anti-inflammatory therapeutic agent in an amount sufficient to gradually release the anti-inflammatory therapeutic agent into the cochlea over an extended period of multiple weeks.

### Claim 7 (depends on 5)

The system of claim 5, wherein the distal port of the therapeutic gel delivery shaft is sized to output a dosage of the self-gelling therapeutic formulation to both seal the cochlear implant lead insertion site and provide the sustained release of the anti-inflammatory therapeutic agent.

### Claim 8 (depends on 1)

The system of claim 1, wherein the therapeutic gel delivery shaft and the visualization shaft are side-by-side shafts being fixedly mounted to the handle in a stationary position relative to one another and extending distally from the handle such that the distal port of the therapeutic gel delivery shaft is positioned distally of the visualization shaft, wherein the transmastoid injector tool further comprises a tip-mounted image capture device fixedly mounted at a distal end of the visualization shaft and oriented toward the distal port of the therapeutic gel delivery shaft so that the tip-mounted image capture device is configured to provide simultaneous imaging of both the therapeutic gel delivery shaft and the self-gelling therapeutic formulation deposited at the cochlear implant lead insertion site of the cochlea.

### Claim 9 (depends on 8)

The system of claim 8, wherein the tip-mounted image capture device at the distal end of the visualization shaft is positioned in a distal-facing orientation and has a maximum width of 1 mm or less.

### Claim 10 (depends on 9)

The system of claim 9, further comprising the treatment actuator device configured to connect with the fluid input port on the handle of the transmastoid injector tool, the treatment actuator device comprising a syringe device including a plunger actuator, a fluid reservoir containing the self-gelling therapeutic formulation, and a flexible tube that extends distally toward the fluid input port on the handle of the transmastoid injector tool.

### Claim 11 (depends on 9)

The system of claim 9, wherein the therapeutic gel delivery shaft extends distally beyond the tip-mounted image capture device at the distal end of the visualization shaft by a distal extension distance of 1 mm to 5 mm.

### Claim 12 (depends on 8)

The system of claim 8, wherein the tip-mounted image capture device is connected with an image data cable extending through a lumen of the visualization shaft proximally toward the handle, wherein the system further comprises:
a video controller configured to receive image data from the tip-mounted image capture device via the image data cable, the video controller comprising at least one video output port to connect with a user interface display to present a location of a distal tip of a therapeutic formulation delivery shaft relative to the cochlear implant lead insertion site.

### Claim 13 (depends on 12)

The system of claim 12, wherein the tip-mounted image capture device is configured to capture the image data of both the distal port of the therapeutic gel delivery shaft and a portion of the therapeutic gel delivery shaft, wherein the video controller is configured to cause the user interface display to present the location of the portion of the therapeutic gel delivery shaft that is distal to the tip-mounted image capture device relative to the cochlear implant lead insertion site.

### Claim 14 (depends on 1)

The system of claim 1, wherein the transmastoid injector tool further comprises a tip-mounted image capture device fixedly mounted at a distal end of the visualization shaft and oriented toward the distal port of the therapeutic gel delivery shaft so that the tip-mounted image capture device is configured to provide simultaneous imaging of both the therapeutic gel delivery shaft and the self-gelling therapeutic formulation deposited at the cochlear implant lead insertion site of the cochlea.

### Claim 15 (depends on 1)

The system of claim 1, further comprising the treatment actuator device, wherein the treatment actuator device includes a fluid reservoir containing the self-gelling therapeutic formulation comprising a multi-arm polyethylene glycol, a crosslinker, and dexamethasone, and the distal port of the therapeutic gel delivery shaft is sized to output a dosage of the self-gelling therapeutic formulation to both seal the cochlear implant lead insertion site and provide a sustained release of the dexamethasone into the cochlea.

### Claim 16 (depends on 15)

The system of claim 15, further comprising a flexible tube extending from the fluid reservoir of the treatment actuator device to the fluid input port of the handle of the transmastoid injector tool.

### Claim 17 (depends on 1)

The system of claim 1, wherein an exterior of the handle forms an undulating pattern that gradually increases in diameter from a proximal end of the handle to a first peak, gradually decreases in diameter from the first peak to a valley, gradually increases in dimeter from the valley to a second peak, and gradually decreases in diameter from the second peak to a distal end of the handle.

### Claim 18 (depends on 17)

The system of claim 17, wherein the exterior of the handle comprises grip edges located at the second peak, the grip edges including ridges that increase a coefficient of friction between fingers of a clinician and the handle as compared with a coefficient of friction between the fingers of the clinician and a smooth surface.

### Claim 19 (depends on 1)

The system of claim 1, wherein the visualization shaft has an exterior diameter that is larger than an outer diameter of the therapeutic gel delivery shaft, and a combined maximum width of the visualization shaft and the therapeutic gel delivery shaft is less than 2 mm.

### Claim 20 (depends on 19)

The system of claim 19, wherein the transmastoid injector tool further comprises a tip-mounted image capture device fixedly mounted at a distal end of the visualization shaft, the tip-mounted image capture device comprising: an image sensor, and a light source configured to emit light distally from the distal end of the visualization shaft so that the image sensor provides direct visualization of the therapeutic gel delivery shaft.
